Source: PR Newswire PRINCETON, N.J., Feb. 27, 2019 /PRNewswire/ -- Sun Pharmaceutical Industries Inc., USA (SPII) today announced that it plans to present 19 abstracts featuring data on ILUMYA™ (tildrakizumab-asmn), a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy, at the 77th Annual Meeting of the American Academy…...